A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

NCT01172392 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

185

Enrollment

OTHER_GOV

Sponsor class

Conditions

Chronic Hepatitis B
AgHbs Negativation

Interventions

DRUG: Pegylated interferon-alpha-2a
DRUG: Nucleotidic or Nucleosidic Treatment

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]